United Kingdom Gout Therapeutics Market Insight
United Kingdom Gout Therapeutics Market is growing at an 6.65% CAGR, driven by rising gout prevalence, aging demographics
United Kingdom Gout Therapeutics Market Insights Forecasts to 2035
- The United Kingdom Gout Therapeutics Market Size Was Estimated at USD 87.8 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 6.65% from 2025 to 2035
- The United Kingdom Gout Therapeutics Market Size is Expected to Reach USD 167.2 Million by 2035
Notable Insights for United Kingdom Gout Therapeutics Market
- By drug class, urate-lowering therapies dominated, accounting for approximately 77% share in 2024, driven by long-term disease
- By therapy type, chronic gout management therapies dominated, holding approximately 73% share, due to increasing recurrent gout flare cases and long-term uric acid control requirements.
- Approximately 3% of the UK adult population is affected by gout, with higher prevalence among elderly individuals and patients with obesity, hypertension, or kidney disease.
- Around 85% of diagnosed patients receive oral urate-lowering medications, while a smaller proportion require biologics or combination therapies for severe or refractory gout cases.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Gout Therapeutics Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Gout Therapeutics Market
- AstraZeneca
- Horizon Therapeutics
- Hikma Pharmaceuticals
- Teva Pharmaceutical Industries
- Novartis
- Pfizer
- Takeda Pharmaceutical Company
- GlaxoSmithKline
- Others
Recent Developments:
- In October 2025: Crystalys Therapeutics secured $205 million in Series A financing to advance global Phase III trials of dotinurad, a once-daily oral URAT1 inhibitor for gout with potential best-in-class efficacy and safety.
- In March 2025: Arthrosi Therapeutics dosed the first patient in the Phase III REDUCE 1 trial evaluating AR882, an oral URAT1 inhibitor for gout and tophaceous gout, with top-line data anticipated in Q2 2026.
Market Segmentation:
United Kingdom Gout Therapeutics Market, By Drug Class
- Urate-Lowering Therapies (Allopurinol, Febuxostat)
- NSAIDs
- Colchicine
- Corticosteroids
- Biologics
- Others
United Kingdom Gout Therapeutics Market, By Route of Administration
- Oral
- Injectable
United Kingdom Gout Therapeutics Market, By End User
- Hospitals & Clinics
- Home Care Settings
- Specialty Rheumatology Centers
United Kingdom Gout Therapeutics Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK Gout Therapeutics Market is expected to grow steadily due to rising obesity rates, aging demographics, and increasing awareness of chronic gout complications. Experts emphasize that urate-lowering therapies will continue dominating treatment approaches, supported by NHS clinical guidelines and broader patient screening initiatives. Advances in biologic therapies, precision medicine, and improved adherence programs are anticipated to enhance long-term disease control and support market expansion through 2035.